Purpose: This study aimed to evaluate the usefulness of the LDN-PSA (LacdiNAc-
glycosylated-prostate specific antigen) in detecting clinically significant prostate cancer in …

Objective To determine the association among prostate cancer gene 3 (PCA 3) score,
Prostate Imaging Reporting and Data System (PI‐RADS) grade and Gleason score, in a …

Introduction: The prostate cancer antigen 3 (PCA3) score has been the first urine assay to
obtain the Food and Drug Administration approval for guiding decisions regarding additional …

Purpose To identify consistently expressed lncRNAs and suitable lncRNAs with high
sensitivity and specificity from multiple independent studies as potential biomarkers for PCa …

Objectives. General frameworks for conducting and reporting health economic evaluations
are available but not specific enough to cover the intricacies of the evaluation of diagnostic …

The Prostate Cancer (PCa) Guidelines Panel have prepared this guidelines document to
assist medical professionals in the evidence-based management of PCa. It must be …

There are two promising urinary RNA biomarkers, prostate cancer antigen 3 (PCA3) and
fusion gene TMPRSS2: ERG, both of which aim to distinguish between men with low-risk …

Background Several liquid biomarker tests have been developed to account for the
limitations of prostate specific antigen (PSA) screening prior to prostate biopsy. African …

Background Diagnosis and monitoring of localized prostate cancer requires discovery and
validation of noninvasive biomarkers. Nuclear magnetic resonance (NMR)-based …

How prostate cancer is diagnosed and staged is an ever-evolving field. It plays a
fundamental role in ensuring the appropriate therapeutic options are offered to the patient …